ClinicalTrials.gg
Not yet recruitingNCT07810114SPAREUpdated Sep 9, 2026

Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer

A Phase 2 interventional study of mFOLFOX6 and Suvemcitug in Rectal Cancer, sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Rectal Neoplasms by Fudan University — 22 open to participants now, 22 under way, 3 of them phase 3. Rectal Neoplasms · Fudan University.

Planned enrollment
32nd of 41
52 · median 134
Started
2026
with 3 others
Phase 2
22 of 43
17 open now
Primary completion
2027-12
later than 13 of 21 live
Registered
42nd of 43
by date

Among the 43 studies in Rectal Neoplasms by Fudan University, this one is the 32nd largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 13 of the 21 other live ones, and was the 42nd registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

22 of the 43 studies in Rectal Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Rectal Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This is a prospective, multicenter, open-label, single-arm Phase II study designed to evaluate the efficacy and safety of total neoadjuvant mFOLFOX6 combined with suvemcitug and enlonstobart in patients with MRI(Magnetic Resonance Imaging)-defined high-risk, mid-rectal, locally advanced rectal adenocarcinoma with pMMR/MSS status.

All enrolled participants will receive 6 cycles of mFOLFOX6 plus suvemcitug and enlonstobart every 2 weeks. After 6 cycles, participants will undergo reassessment with pelvic MRI and systemic imaging. Participants who achieve at least 20% tumor regression on MRI without new high-risk radiologic features will continue with 2 additional cycles of mFOLFOX6 followed by radical total mesorectal excision surgery, without routine pelvic radiotherapy. Participants who do not meet the predefined regression threshold or show disease progression will receive long-course chemoradiotherapy with concurrent capecitabine, followed by 3 cycles of mFOLFOX6 and radical surgery.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years, male or female.
  2. confirmed rectal adenocarcinoma.
  3. pMMR or MSS status confirmed by genetic testing or immunohistochemistry.
  4. Tumor lower margin located 5-12 cm from the anal verge, based on colonoscopy or MRI, consistent with mid-rectal cancer.
  5. Pelvic MRI showing high-risk locally advanced rectal cancer, meeting at least one of the following criteria: cT3c/d, defined as tumor extension >5 mm beyond the muscularis propria; cN2 disease, defined as >=4 regional lymph nodes; definite extramural venous invasion positivity.
  6. No distant metastasis confirmed by chest and abdominal imaging, including contrast-enhanced CT or MRI.
  7. performance status of 0 or 1.
  8. Adequate organ function, including >=1.5 x 10\^9/L; count >=100 x 10\^9/L; >=9 g/dL; and AST \<=2.5 x ; total \<=1.5 x upper limit of normal; serum creatinine \<=1.5 x upper limit of normal or >=50 mL/min.
  9. Not pregnant or breastfeeding. Participants of must agree to use effective during study treatment and for the protocol-specified period after the last dose.
  10. Voluntary participation with signed written .

Exclusion criteria

Exclusion Criteria:

  1. Imaging evidence of cT4 disease, mesorectal fascia positivity, or lateral lymph node .
  2. Prior pelvic radiotherapy or prior systemic antitumor treatment for the current disease, including chemotherapy, targeted therapy, or immunotherapy.
  3. Special histologic subtypes, including mucinous adenocarcinoma, signet-ring cell carcinoma, undifferentiated carcinoma, or other special histologic types.
  4. Known allergy or to any component of the study drugs, including oxaliplatin, 5-fluorouracil, suvemcitug, or enlonstobart.
  5. Active or previous severe disease, including systemic lupus erythematosus or inflammatory bowel disease, or long-term use of systemic agents.
  6. Serious cardiovascular events within 6 months, including acute myocardial infarction or stroke, hypertension, or class III-IV heart failure.
  7. Active infection, including active tuberculosis, uncontrolled or C, or infection with high viral load.
  8. Other within 5 years, except cured localized skin cancer or carcinoma in situ.
  9. Pregnancy or breastfeeding.
  10. Inability to undergo MRI examination.
  11. Multiple primary colorectal cancers.
  12. Intestinal obstruction, intestinal perforation, or high risk of obstruction or perforation.
  13. Hypertension that cannot be controlled to the normal range with antihypertensive therapy, defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg.
  14. NYHA class III-IV cardiac insufficiency or \<50% on echocardiography.
  15. Proteinuria, defined as urine protein >1+ at screening, or urine protein 1+ that does not return to normal on repeat testing within 24 hours.
  16. Definite tendency for gastrointestinal bleeding, including active local ulcerative lesions with fecal occult blood positivity of ++; history of melena or hematemesis within 2 months; high risk of bleeding such as grade >=3 bleeding within 6 months, hemoptysis >=2.5 mL per episode, imaging evidence of tumor invasion into major blood vessels, or bleeding risk deemed unacceptable by the investigator.
  17. High risk of gastrointestinal perforation or fistula, including gastrointestinal perforation or active peptic ulcer within 6 months, or pelvic tumor invasion of the bladder or rectum with potential fistula risk as judged by the investigator.
  18. Coagulation abnormality, including >1.5 or APTT >1.5 x , with bleeding tendency.
  19. Chronic unhealed wound or fracture; major surgery within 4 weeks; or severe traumatic injury, fracture, or ulcer within 4 weeks.
  20. Any condition that, in the investigator's judgment, makes the participant unsuitable for enrollment or unlikely to comply with follow-up.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    mFOLFOX6 combined with suvemcitug and enlonstobart

    Participants will receive total neoadjuvant therapy with mFOLFOX6 plus suvemcitug and enlonstobart for 6 cycles. After interim radiologic reassessment, participants with MRI tumor regression \>=20% and no new high-risk radiologic findings will continue with 2 additional cycles of mFOLFOX6 followed by radical TME(Total Mesorectal Excision) surgery without routine pelvic radiotherapy. Participants with tumor regression \<20% or disease progression will receive long-course pelvic chemoradiotherapy with concurrent capecitabine, followed by 3 cycles of mFOLFOX6 and radical TME surgery.

    Drug: mFOLFOX6 · Drug: Suvemcitug · Drug: Enlonstobart · Radiation: Pelvic Chemoradiotherapy · Procedure: Total Mesorectal Excision

Interventions

  • DrugmFOLFOX6

    Oxaliplatin 85 mg/m2 IV over 2 hours on Day 1; leucovorin calcium 400 mg/m2 IV over 2 hours on Day 1; 5-fluorouracil 400 mg/m2 IV bolus on Day 1; 5-fluorouracil 2400 mg/m2 continuous IV infusion over 46-48 hours;every 2 weeks, for 6 cycles during the initial total neoadjuvant treatment phase. Participants meeting the predefined MRI regression criterion will receive 2 additional cycles of mFOLFOX6 before surgery. Participants requiring chemoradiotherapy will receive 3 additional cycles of mFOLFOX6 after long-course chemoradiotherapy before surgery.

  • Suvemcitug 2 mg/kg IV infusion on Day 1 of each 14-day cycle, every 2 weeks, for 6 doses during the initial total neoadjuvant treatment phase.

  • Enlonstobart 240 mg IV infusion on Day 1 of each 14-day cycle, every 2 weeks, for 6 doses during the initial total neoadjuvant treatment phase.

  • RadiationPelvic Chemoradiotherapy

    Used selectively for participants who do not achieve the predefined interim MRI regression threshold or who show disease progression. 45-50.4 Gy in 25-28 fractions. Oral capecitabine during radiotherapy.

  • ProcedureTotal Mesorectal Excision

    For participants omitting radiotherapy: approximately 2-4 weeks after completion of total neoadjuvant systemic therapy. For participants receiving chemoradiotherapy: after long-course chemoradiotherapy and subsequent mFOLFOX6 treatment, according to investigator assessment.

06

What researchers measure

Primary outcomes

  1. Pathologic Complete Response Rate

    Time frame: Perioperative : at the time of surgery for pCR(Pathologic Complete Response Rate).

Secondary outcomes

  1. R0 Resection Rate

    Time frame: Perioperative : at the time of surgery.

  2. Circumferential Resection Margin Negative Rate

    Time frame: Perioperative : at the time of surgery.

  3. Major Pathologic Response Rate

    Time frame: Perioperative : at the time of surgery.

  4. Proportion of Participants Receiving Pelvic Radiotherapy

    Time frame: At the end of Cycle 6 (each cycle is 14 days)"

  5. Successful Radiotherapy Omission Rate

    Time frame: From enrollment to surgery.

  6. Three-Year Disease-Free Survival

    Time frame: Up to 3 years after surgery

  7. Quality of life will be evaluated using the European O-rganization for Reasearch and Treatment of Cancer Quality of Life Questionnaire-C30(EORTC QLQ-C30) (range 0-100).

    It evaluates the quality of life from 30 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.

    Time frame: Baseline, At the end of Cycle 6 (each cycle is 14 days),Perioperative

Other outcomes

  1. Correlation between changes in plasma cell-free RNA (cfRNA) signature scores and tumor regression.

    The correlation between longitudinal changes in plasma cell-free RNA (cfRNA) signature scores and rumor regression will be assessed. Plasma cfRNA will be measured by high-throughput RNA sequencing using the SLiPiR-seq (Splint Ligation and Phosphate-independent RNA Sequencing) method. Normalized cfRNA expression data will be used to calculate predefined or exploratory transcriptomic signature scores, including tumor-related and immune-related signature scores. The change in each cfRNA signature score from baseline (T1, before initiation of neoadjuvant treatment) to the preoperative assessment (T2, after completion of neoadjuvant treatment) will be calculated as the absolute and/or relative change in normalized signature score. The strength of the relationship between the change in cfRNA signature score and tumor regression will be quantified using the Spearman rank correlation coefficient.

    Time frame: Baseline,At the end of Cycle 6 (each cycle is 14 days),

07

Study locations

1 site
  • Department of General Surgery, Zhongshan Hospital, Fudan University
    Shanghai, 200032, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2027, 15 months later.

Of 228 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 15 months is below that.

Counting every sponsor, half of 242 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Sep 9, 2026
StartEst.
Aug 28, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2030
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07810114
Lead sponsor
Fudan University
Responsible party
Xu jianmin (Director of the Department of Colorectal Surgery, Fudan University) — Principal investigator
First posted
Sep 9, 2026
Start date
Aug 28, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Sep 9, 2026

Study contacts

Wentao Tang
Contact
tangwt1988@163.com
18317121626

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Suvemcitug · Enlonstobart

Start the discussion